Zevalin ibritumomab tiuxetan: Phase II started

Spectrum began an open-label, North American Phase II trial to evaluate IV Zevalin plus rituximab with or without motexafin gadolinium, a radiation and chemotherapy sensitizing agent, in about 100 patients.

Zevalin is approved in the U.S. to treat previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy and to treat relapsed or refractory, low-grade or follicular B cell NHL. Spectrum markets Zevalin in the U.S. and has ex-U.S. rights to the cancer drug from Bayer (see BioCentury, Jan. 30). Zevalin is approved in more than 40 countries outside the U.S. for follicular B cell NHL, including countries in Europe, Latin America and Asia. ...